

KT-474

## Chemical Properties

CAS No. : 2432994-31-3


Formula: C44H49F2N11O6

Molecular Weight: 865.93

Store at low temperature

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



## Biological Description

Description	KT-474 (KYM-001) is a PROTAC degrader targeting interleukin-1 receptor-associated kinase 4 (IRAK4) with antitumor activity for the study of autoimmune, inflammatory, and cardiovascular disease disorders.
Targets(IC50)	Apoptosis,IRAK,PROTACs

## Solubility Information

Solubility	DMSO: 80 mg/mL (92.39 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween-80+45% Saline: 3.3 mg/mL (3.81 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

## Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.1548 mL	5.7741 mL	11.5483 mL
5 mM	0.231 mL	1.1548 mL	2.3097 mL
10 mM	0.1155 mL	0.5774 mL	1.1548 mL
50 mM	0.0231 mL	0.1155 mL	0.231 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Nello Mainolfi, et al. Irak degraders and uses thereof. Patent WO2020113233A1.

Ackerman L, et al. IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial. Nat Med. 2023 Dec;29(12):3127-3136.

Joseph F. Kelleher, et al. Abstract LB-272: KYM-001, a first-in-class oral IRAK4 protein degrader, induces tumor regression in xenograft models of MYD88-mutant ABC DLBCL alone and in combination with BTK inhibition. Cancer Res (2019) 79 (13\_Supplement): LB-272.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481